Publications in VIVO

Co-author Network

Charles Windon, MD

Person

Positions

Assistant Professor, University of California, San Francisco

Clinical Disciplines

Neurology

Publications
Other
View All

Selected Publications

article
1. Perceptions about dementia clinical trials among underrepresented populations: A nationally representative survey of U.S. dementia caregivers.. Research square. 2024
2. Promoting Growth in Behavioral Neurology: A Path Forward.. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology. 37:49-56. 2024
3. Underrepresented and Underserved Populations in Neurological Research.. Seminars in neurology. 44:168-177. 2024
4. Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 20:2089-2101. 2024
5. Promoting Growth in Behavioral Neurology: A Path Forward. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology. 2024
6. Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2024
7. Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS).. Alzheimer's & dementia : the journal of the Alzheimer's Association. 19 Suppl 9:S98-S114. 2023
8. 64 Neuroimaging Evidence of Neurodegenerative Disease in Former Professional American Football Players Who “Fail” Validity Testing: A Case Series. Journal of the International Neuropsychological Society : JINS. 2023
9. Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer′s Disease Study (LEADS). Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2023
10. Amyloid‐, tau‐, and FDG‐PET in amyloid‐negative patients clinically diagnosed with early‐onset Alzheimer’s disease in the LEADS study 2023
11. Amyloid‐, tau‐, and FDG‐PET in amyloid‐negative patients clinically diagnosed with early‐onset Alzheimer’s disease in the LEADS study 2023
12. Amyloid‐PET, tau‐PET, and their association in sporadic early‐onset Alzheimer’s Disease: Cross‐sectional and longitudinal data from the LEADS study 2023
13. Comparison of Expert Reads vs. Local Clinical Reads of Amyloid PET Scans in IDEAS 2023
14. Comparison of Expert Reads vs. Local Clinical Reads of Amyloid PET Scans in IDEAS 2023
15. Perceptions about Dementia Clinical Trials 2023
16. Quantitative Amyloid‐PET in Real‐World Practice: Lessons from the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study 2023
17. Regional patterns of pathological tau accumulation in sporadic early‐onset Alzheimer’s disease: Longitudinal tau‐PET in the LEADS Cohort 2023
18. Towards the future of ADRD diagnosis: combination of a brief digital cognitive battery and plasma biomarkers for diagnosis and prognosis of disease 2023
19. Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study.. JAMA neurology. 79:1139-47. 2022
20. Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI.. Alzheimer's & dementia (Amsterdam, Netherlands). 14:-. 2022
21. 18F‐MK‐6240 Tau PET as a Biomarker for Chronic Traumatic Encephalopathy: Case Series of 10 Symptomatic Former National Football League Players 2022
22. Amyloid Negative, Highly Tau Positive: Clinical Characterization of a Rare Biomarker Profile 2022
23. Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2022
24. Quantitative analysis of 6,150 real‐world amyloid Positron Emission Tomography (PET) scans from the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) study 2022
25. Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study. JAMA Neurology. 2022
26. Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California.. JAMA neurology. 78:657-665. 2021
27. Perils of Race-Based Norms in Cognitive Testing: The Case of Former NFL Players.. JAMA neurology. 78:377-378. 2021
28. Association of remote mild traumatic brain injury with cortical amyloid burden in clinically normal older adults.. Brain imaging and behavior. 15:2417-2425. 2021
29. Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California. JAMA Neurology. 2021
30. Association of remote mild traumatic brain injury with cortical amyloid burden in clinically normal older adults. Brain Imaging and Behavior. 2021
31. Comparison of plasma and CSF biomarkers across ethnoracial groups in ADNI 2021
32. IDEAS and New IDEAS: Amyloid PET in diverse populations 2021
33. Perils of Race-Based Norms in Cognitive Testing The Case of Former NFL Players. JAMA Neurology. 2021
34. Rapid Revascularization of Simultaneous Bilateral ICA Occlusions causing Coma. Neurology. 2018
35. Neuropeptide VGF Promotes Maturation of Hippocampal Dendrites That Is Reduced by Single Nucleotide Polymorphisms. International Journal of Molecular Sciences. 2017
36. Neuropeptide VGF Promotes Maturation of Hippocampal Dendrites That Is Reduced by Single Nucleotide Polymorphisms. International journal of molecular sciences. 18:612. 2017
37. The Antidepressant-Like Agent Neuropeptide VGF: Mechanism of Action on Adult Neurogenesis and Effect of SNPs on Expression Levels. Biological Psychiatry. 2014
38. Redefining Human Vitamin D Sufficiency: Back to the Basics. Bone Research. 2013
39. Redefining Human Vitamin D Sufficiency: Back to the Basics. Bone research. 1:2-10. 2013
document
1. Vascular Cognitive Impairment 2024
2. Rapid Revascularization of Simultaneous Bilateral ICA Occlusions causing Coma. Neurology. 2018
3. The Antidepressant-Like Agent Neuropeptide VGF: Mechanism of Action on Adult Neurogenesis and Effect of SNPs on Expression Levels. Biological psychiatry. 2014